logo

Quick Facts

Share SHARE

Agios Pharmaceuticals, Inc. (AGIO) reported updated data from its pyruvate kinase-R (PKR) activator demonstrating the potential for the first disease-modifying treatment for patients with pyruvate kinase deficiency. DRIVE PK is an ongoing global open-label, Phase 2, safety and efficacy trial evaluating...

Verastem, Inc. (VSTM) reported long-term follow-up data from the DYNAMO study, which met its primary endpoint of Overall Response Rate at the final analysis. DYNAMO is a Phase 2 clinical study evaluating duvelisib, the company's investigational oral monotherapy, dual inhibitor of phosphoinositide-3-kinase...

Novo Nordisk (NVO) announced the headline results from a 52-week double-blind phase 2 clinical trial with once-daily subcutaneous semaglutide investigating safety and potential for inducing and maintaining weight loss in people with obesity. In the trial, 957 people with obesity were randomised to...

Forestar Group Inc. (FOR) announced that it received a revised binding proposal from D.R. Horton Inc. (DHI) to acquire 75% of the outstanding shares of Forestar common stock for $17.75 per share in cash (an increase from D.R. Horton's previous offer of $16.25 in cash per share to acquire 75% of the outstanding...

Alexion Pharmaceuticals Inc. (ALXN) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion to extend the current therapeutic indication for Soliris (eculizumab) to include the treatment of refractory generalized myasthenia gravis...

Biogen (BIIB) said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA has issued a positive opinion for IMRALDI (also known as SB5), an adalimumab biosimilar candidate referencing Humira. The positive opinion will now be referred to the European...

RWE AG (RWEOY.PK) announced the company's Executive Board intends to propose to the annual general meeting in 2018 a one-off special dividend amounting to 1.00 euros per common and preferred share. The special dividend payment shall be made as a one-off payment in addition to the 0.50 euros dividend...

ParkerVision Inc. (PRKR) said that the Regional Court of Munich is holding its decision in the ParkerVision v. Apple case until after the German Federal Patent Court rules on the related pending nullity (validity) action. The Company's final resolution in its German case against LG is also pending...

BlackBerry Limited (BBRY, BB.TO) announced it has received acceptance from the Toronto Stock Exchange with respect to a normal course issuer bid to purchase for cancellation up to 31 million BlackBerry common shares, representing approximately 6.4% of the outstanding public float as at May 31, 2017....

Finish Line Inc. (FINL) said that it still expects comparable store sales to increase in the low-single digits range and adjusted earnings per share to be between $1.12 and $1.23 for the 53 week fiscal year ending March 3, 2018. Analysts polled by Thomson Reuters expect the company to report earnings...

Accenture (ACN) said that it has completed the termination of its U.S. Pension Plan, which was previously announced in March 2016, by entering into agreements with American General Life Insurance Company or AGL - a subsidiary of American International Group Inc. (AIG) - and Massachusetts Mutual Life...

Novartis (NVS) announced the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA has adopted a positive opinion recommending approval of Kisqali (ribociclib) in combination with an aromatase inhibitor for treatment of postmenopausal women with hormone receptor...

Novartis (NVS) announced results from additional analyses of the ENESTfreedom and ENESTop clinical trials, which found that about half of adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia or CML in the chronic phase or CP who discontinued Tasigna (nilotinib) remain in...

Novartis (NVS) announced updated results from the ELIANA clinical trial demonstrating CTL019 or tisagenlecleucel remission rates are maintained at six months in relapsed/refractory (r/r) pediatric and young adult patients with B-cell acute lymphoblastic leukemia or ALL. These data from this pivotal...

Genentech, a member of the Roche Group (RHHBY), announced that it will present new post-hoc analyses from the OCREVUSTM (ocrelizumab) Phase III clinical trial program in people with relapsing and primary progressive forms of multiple sclerosis RMS and PPMS) at the 3rd Congress of the European Academy...

Follow RTT